<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmaceutical Product Guide &#187; Diabetes</title>
	<atom:link href="http://www.pharmaceuticalproductguide.com/blog/tag/diabetes/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmaceuticalproductguide.com/blog</link>
	<description>A comprehensive guide to pharmaceutical products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 09:15:33 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Diabetes drug Victoza Gets FDA Approval</title>
		<link>http://www.pharmaceuticalproductguide.com/blog/2010/01/28/diabetes-drug-victoza-gets-fda-approval/</link>
		<comments>http://www.pharmaceuticalproductguide.com/blog/2010/01/28/diabetes-drug-victoza-gets-fda-approval/#comments</comments>
		<pubDate>Fri, 29 Jan 2010 04:56:02 +0000</pubDate>
		<dc:creator>Kimberly O'Brien</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[FDA Approval]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[liraglutide]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[Victoza]]></category>

		<guid isPermaLink="false">http://www.pharmaceuticalproductguide.com/blog/?p=200</guid>
		<description><![CDATA[The FDA has approved Novo Nordisk’s new Diabetes drug Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in adults. Victoza, also known as Liraglutide, was launched in European markets in 2009 and has gained regulatory approval in Japan last week. Victoza belongs to a class of medicines known as glucagon-like peptide-1 (GLP-1) receptor [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2010/01/Victoza.png"><img class="alignleft size-full wp-image-201" style="margin: 5px" src="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2010/01/Victoza.png" alt="Victoza" width="200" height="53" /></a>The FDA has approved Novo Nordisk’s new Diabetes drug Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in adults. Victoza, also known as Liraglutide, was launched in European markets in 2009 and has gained regulatory approval in Japan last week. Victoza belongs to a class of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists, which help the pancreas make more insulin after eating a meal.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmaceuticalproductguide.com/blog/2010/01/28/diabetes-drug-victoza-gets-fda-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Generex receives price approval for Oral-lyn</title>
		<link>http://www.pharmaceuticalproductguide.com/blog/2009/10/23/generex-receives-price-approval-for-oral-lyn/</link>
		<comments>http://www.pharmaceuticalproductguide.com/blog/2009/10/23/generex-receives-price-approval-for-oral-lyn/#comments</comments>
		<pubDate>Fri, 23 Oct 2009 17:36:04 +0000</pubDate>
		<dc:creator>Kimberly O'Brien</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[FDA Approval]]></category>
		<category><![CDATA[diabetes mellitus]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Generex]]></category>
		<category><![CDATA[Generex Biotechnology]]></category>
		<category><![CDATA[IND program]]></category>
		<category><![CDATA[Oral-lyn]]></category>

		<guid isPermaLink="false">http://www.pharmaceuticalproductguide.com/blog/?p=144</guid>
		<description><![CDATA[Generex Biotechnology Corporation has been granted price approval by the US Food and Drug Administration approval for the use of Generex Oral-lyn(TM) under the FDA&#8217;s Treatment Investigational New Drug (IND) program. Generex was previously granted the FDA approval for the use of Generex Oral-lyn(TM) in patients with Type 1 or Type 2 diabetes mellitus under [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2009/10/generex.png"><img class="alignright size-full wp-image-145" style="margin: 5px" src="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2009/10/generex.png" alt="generex" width="200" height="25" /></a>Generex Biotechnology Corporation has been granted price approval by the US Food and Drug Administration approval for the use of Generex Oral-lyn(TM) under the FDA&#8217;s Treatment Investigational New Drug (IND) program. Generex was previously granted the FDA approval for the use of Generex Oral-lyn(TM) in patients with Type 1 or Type 2 diabetes mellitus under the FDA&#8217;s &#8220;Treatment IND&#8221; rules.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmaceuticalproductguide.com/blog/2009/10/23/generex-receives-price-approval-for-oral-lyn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
